Title:Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing
Volume: 15
Issue: 4
Author(s): Ulrich Siler, Anna Paruzynski, Heidi Holtgreve-Grez, Elena Kuzmenko, Ulrike Koehl, Eleonore D. Renner, Canan Alhan, , Arjan A. van de Loosdrecht, Joachim Schwäble, Thomas Pfluger, Joelle Tchinda, Markus Schmugge, Anna Jauch, Sonja Naundorf, Klaus Kühlcke, Gundula Notheis, Tayfun Güngor, Christof v. Kalle, Manfred Schmidt and Manuel Grez, Reinhard Seger and Janine Reichenbach
Affiliation:
关键词:
异基因造血干细胞移植，慢性肉芽肿病，亲嗜性病毒整合位点1，基因治疗，原发性免疫缺陷，逆转录病毒载体，STAT3，转录激活
摘要: We report on a series of sequential events leading to long-term survival and cure of pediatric X-linked chronic
granulomatous disease (X-CGD) patients after gamma-retroviral gene therapy (GT) and rescue HSCT. Due to therapyrefractory
life-threatening infections requiring hematopoietic stem cell transplantation (HSCT) but absence of HLAidentical
donors, we treated 2 boys with X-CGD by GT. Following GT both children completely resolved invasive Aspergillus
nidulans infections. However, one child developed dual insertional activation of ecotropic viral integration site 1
(EVI1) and signal transducer and activator of transcription 3 (STAT3) genes, leading to myelodysplastic syndrome (MDS)
with monosomy 7. Despite resistance to mismatched allo-HSCT with standard myeloablative conditioning, secondary intensified
rescue allo-HSCT resulted in 100 % donor chimerism and disappearance of MDS. The other child did not develop
MDS despite expansion of a clone with a single insertion in the myelodysplasia syndrome 1 (MDS1) gene and was
cured by early standard allo-HSCT. The slowly developing dominance of clones harboring integrations in MDS1-EVI1
may guide clinical intervention strategies, i.e. early rescue allo-HSCT, prior to malignant transformation. GT was essential
for both children to survive and to clear therapy-refractory infections, and future GT with safer lentiviral self-inactivated
(SIN) vectors may offer a therapeutic alternative for X-CGD patients suffering from life-threatening infections and lacking
HLA-identical HSC donors.
